Fatty Liver and Fatty Heart-Where do They Stand in the AMIS Syndrome?

被引:1
|
作者
Lautt, W. Wayne [1 ]
Ming, Zhi [1 ]
Legare, Dallas J. [1 ]
Chowdhury, Kawshik K. [1 ]
Hatch, Grant M. [1 ]
Wang, Hui Helen [1 ]
机构
[1] Univ Manitoba, Dept Pharmacol & Therapeut, Coll Med, Fac Hlth Sci, A224-753 McDermot Ave, Winnipeg, MB R3E 0T6, Canada
来源
HEALTHCARE | 2015年 / 3卷 / 03期
基金
加拿大健康研究院;
关键词
meal-induced insulin sensitization (MIS); absence of meal-induced insulin sensitization (AMIS); hepatic insulin sensitizing substance (HISS); non-alcoholic fatty liver disease (NAFLD); rapid insulin sensitivity test (RIST); S-adenosylmethionine; vitamins E and C (SAMEC);
D O I
10.3390/healthcare3030666
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Meal-induced insulin sensitization (MIS) refers to the augmented glucose uptake response to insulin following a meal. Absence of MIS (AMIS) causes significant decrease in post-meal glucose disposal leading to postprandial hyperglycemia, hyperinsulinemia, hyperlipidemia, adiposity, increased free radical stress, and a cluster of progressive metabolic, vascular, and cardiac dysfunctions referred to as the AMIS syndrome. We tested the hypothesis that fat accumulation in the liver and heart is part of the AMIS syndrome. Questions examined in the study: (1) Is prediabetic fat accumulation in the heart and liver a component of the AMIS syndrome? (2) Is fatty liver a cause or consequence of peripheral insulin resistance? (3) Is early cardiac dysfunction in the AMIS syndrome attributable to fat accumulation in the heart? and (4) Can the synergistic antioxidant cocktail SAMEC (S-adenosylmethionine, vitamin E, and vitamin C), known to benefit MIS, affect cardiac and hepatic triglyceride levels? Four animal models of AMIS were used in aged male Sprague-Dawley rats (52 weeks +/- sucrose +/- SAMEC), compared with young controls (nine weeks). Fat accumulation in the heart was not significant and therefore cannot account for the early cardiac dysfunction. Hepatic triglycerides increased only in the most severe AMIS model but the small changes correlated with the much more rapidly developing peripheral adiposity. Systemic adiposity represents an early stage, whereas accumulation of cardiac and hepatic triglycerides represents a late stage of the prediabetic AMIS syndrome. Fat accumulation in the liver is a consequence, not a cause, of AMIS. SAMEC protected against the sucrose effects on whole body adiposity and hepatic lipid accumulation.
引用
收藏
页码:666 / 682
页数:17
相关论文
共 50 条
  • [1] Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
    Mikolasevic, Ivana
    Filipec-Kanizaj, Tajana
    Mijic, Maja
    Jakopcic, Ivan
    Milic, Sandra
    Hrstic, Irena
    Sobocan, Nikola
    Stimac, Davor
    Burra, Patrizia
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (14) : 1491 - 1506
  • [2] Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
    Mikolasevic, Ivana
    Pavic, Tajana
    Kanizaj, Tajana Filipec
    Bender, Darija Vranesic
    Domislovic, Viktor
    Krznaric, Zeljko
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 2020
  • [3] Metabolic fatty liver syndromes: where do we stand in 2024?
    Chan, Wah-Kheong
    George, Jacob
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (04) : 613 - 614
  • [4] Fatty liver and nonalcoholic steatohepatitis - Where do we stand and where are we going?
    Lonardo, A
    DIGESTIVE DISEASES, 1999, 17 (02) : 80 - 89
  • [5] Nonalcoholic fatty liver disease and liver transplantation-Where do we stand?
    Ivana Mikolasevic
    Tajana Filipec-Kanizaj
    Maja Mijic
    Ivan Jakopcic
    Sandra Milic
    Irena Hrstic
    Nikola Sobocan
    Davor Stimac
    Patrizia Burra
    World Journal of Gastroenterology, 2018, 24 (14) : 1491 - 1506
  • [6] Treatment of nonalcoholic fatty liver disease: Where do we stand an overview
    Dajani, Asad
    AbuHammour, Adnan
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2016, 22 (02): : 91 - 105
  • [7] Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
    Shaheen Tomah
    Naim Alkhouri
    Osama Hamdy
    Clinical Diabetes and Endocrinology, 6 (1):
  • [8] Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
    Spooner, Melinda H.
    Jump, Donald B.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2019, 22 (02): : 103 - 110
  • [9] Heart fatty acid binding protein in the diagnosis of myocardial infarction: Where do we stand today?
    Colli, Andrea
    Josa, Miguel
    Pomar, Jose Luis
    Mestres, Carlos Alberto
    Gherli, Tiziano
    CARDIOLOGY, 2007, 108 (01) : 4 - 10
  • [10] Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
    Mitrovic, Bojan
    Gluvic, Zoran M.
    Obradovic, Milan
    Radunovic, Maja
    Rizzo, Manfredi
    Banach, Maciej
    Isenovic, Esma R.
    ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (04) : 884 - 894